Publications

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.

Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A.  2010.  DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.. Blood. 116(20):e81-9.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM et al..  2013.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.. Cell Rep. 4(3):578-88.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.

Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, Gomes EMDaGama, Yang C, Patel MR, Shrestha L et al..  2014.  Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.. ACS Chem Biol. 9(8):1698-705.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.  2014.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Goldstein RL, Yang SNing, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G et al..  2015.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.. J Clin Invest. 125(12):4559-71.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.  2015.  The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.. Oncogene. 34(9):1073-82.

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al..  2016.  Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.